![](https://endpts.com/wp-content/uploads/2019/12/GettyImages-1164535264-scaled.jpg)
Amarin CEO John Thero discussing the company's plans for Vascepa, August 2019 — via Bloomberg
Amarin wins a blockbuster approval from the FDA. Now everyone can shift focus to the patent
For all those people who could never quite believe that Amarin $AMRN would get an expanded label with blockbuster implications, the stress and anxiety …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.